Experienced in Interrupted Aortic Arch

Philippe A. Soyer

Paris, FR 
Experienced in Interrupted Aortic Arch
Paris, FR 
OverviewLocationsClinical Research

Overview

Philippe Soyer practices in Paris, France. Mr. Soyer is rated as an Experienced expert by MediFind in the treatment of Interrupted Aortic Arch. His top areas of expertise are Sclerosing Mesenteritis, Neuroendocrine Tumor, Pancreatic Cancer, Liver Embolization, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 309 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Interrupted Aortic Arch.

Gender
Male

Locations

Paris, France
Other Locations
CHI Poissy St Germain, 10, Rue Du Champ Gaillard, BP 3082, Poissy, 78303, France
Reims, 51092, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer
Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Irinotecan Liposomal Injection, 5-FU/LV, Nab-Paclitaxel, Gemcitabine
Study Phase: Phase 2
Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial
Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug
Study Drugs: Hormonotherapy, Chemotherapy then Hormonotherapy
Study Phase: Phase 3
View 1 Less Clinical Trial

309 Total Publications

CARJ 2025: Year in Review.
CARJ 2025: Year in Review.
Journal: Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
Published: August 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Soyer's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 60 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile